Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
NCT Number: NCT00556361
To assess whether the drug ketamine given prior to cardiopulmonary bypass can decrease injury to the cells in the brain.
Looking for future studies?
Notify MeUp to 1 year
All sexes
Interventional
Phase 2
Little Rock, Arkansas, 72202, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
Time frame: within 48 hours
Time frame: within 48 hours
Time frame: one month
Arkansas Children's Hospital Research Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04667455
Aortopulmonary Septal Defect, Aortopulmonary Window
Lund, Skåne County, Sweden
View Trial DetailsNCT06298344
Atrial Septal Defect, Avitaminosis
Medan, North Sumatera, Indonesia
View Trial DetailsNCT05688670
Atrial Septal Defect, Cardiovascular Abnormalities
Durham, North Carolina, United States
View Trial DetailsNCT05939713
Cardiovascular Abnormalities, Cardiovascular Diseases
Kaohsiung City, Taiwan
View Trial Details